Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10035966HBVENSG00000085563.15protein_codingABCB1YesNo5243A4D1D2
P08183
TVIS30067436HIVENSG00000085563.15protein_codingABCB1YesNo5243A4D1D2
P08183
TVIS20061554HPVENSG00000085563.15protein_codingABCB1YesNo5243A4D1D2
P08183
TVIS20061565HPVENSG00000085563.15protein_codingABCB1YesNo5243A4D1D2
P08183
TVIS20061861HPVENSG00000085563.15protein_codingABCB1YesNo5243A4D1D2
P08183
TVIS44008599HTLV-1ENSG00000085563.15protein_codingABCB1YesNo5243A4D1D2
P08183
TVIS44039492HTLV-1ENSG00000085563.15protein_codingABCB1YesNo5243A4D1D2
P08183
TCGA Plot Options
Drug Information
GeneABCB1
DrugBank IDDB14065
Drug NameLomerizine
Target IDBE0001032
UniProt IDP08183
Regulation Typeinhibitor
PubMed IDs16539840; 11379779
CitationsJi BS, He L, Li XQ, Liu GQ: CJZ3, a lomerizine derivative, modulates P-glycoprotein function in rat brain microvessel endothelial cells. Acta Pharmacol Sin. 2006 Apr;27(4):414-8. doi: 10.1111/j.1745-7254.2006.00294.x.@@Shiraki N, Hamada A, Ohmura T, Tokunaga J, Oyama N, Nakano M: Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biol Pharm Bull. 2001 May;24(5):555-7.
GroupsExperimental
Direct Classification
SMILESCOC1=CC=C(CN2CCN(CC2)C(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)C(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL29188